Quick Links






Jeffrey Wang, BS, PhD

Professor, Pharmaceutical Sciences, Director, Graduate Education

College of Pharmacy

E-Mail: jwang@westernu.edu

Phone: 909-469-5413


Ph.D. (Pharmaceutical Sciences)
1995 University of Southern California

1986 School of Pharmacy, Shanghai Medical University, China

Research Interest

Reversible lipidization of proteins and peptides. Oral delivery of protein and peptide drugs. Bioconjugation chemistry. Fusion protein design and expression. Prodrug design and synthesis. Analytical assay development and validation. Pre-clinical pharmacokinetics and drug metabolism. Nanoparticle and liposome formulation development.

Research Grant

  1. Vancomycin product development
    Nevakar, LLC
    Co-Principal Investigator
    2016 – 2017
  2. Preclinical Development of an Orally Effective Factor IX-based Agent for the Prophylaxis and Treatment of Bleeding Episodes in Hemophilia B Patients
    Novo Nordisk, Inc.
    Principal Investigator
    2015 – 2017
  3. Combinatorial nanotechnology-based regimens for pancreatic cancer chemoprevention
    National Institutes of Health R15 research grant
    2014 – 2017


  1. Chan P, Wang Z, Xie C, Huang Y, Wang J. Antioxidant nutraceuticals and prostate cancer. In: Antioxidant Nutraceuticals: Preventive Healthcare and Applications. Pathak S and Cao C (Eds). RCS Press, 2017 (in press).
  2. Thakkar A, Grandhi BK, Wang J, and Prabhu S. PI3K and ERK1/2 pathway inhibitor enhances chloroquine and aspirin mediated autophagy inhibition in pancreatic cancer cells. Oncol Rep (in press).
  3. Ding B, Zhang W, Wu X, Wang J, Xie C, Huang X, Zhan S, Zheng Y, Huang Y, Xu N, Ding X, Gao S. Superiority of DR5 mAb-mediated DTIC-loaded immuno-nanoparticles in the therapy of malignant melanoma-bearing nude mice: Enhanced drug target and tumoricidal efficacy with reduced systemic toxicity. Oncotarget, 7, 57160-70, 2016.
  4. Wang Z, Ravula R, Yeung S, Liu M, Lau B, Hao J, Wang J, Lam WK, Chow MSS, Huang Y. Overcoming chemoresistance in prostate cancer with Chinese medicine Tripterygium wilfordii via multiple mechanisms. Oncotarget, 7, 61246-61, 2016.
  5. Thakkar A, Chenreddy S, Khamas W, Wang J, and Prabhu S. Preclinical systemic toxicity evaluation of chitosan-solid lipid nanoparticles encapsulated aspirin, curcumin and free sulforaphane (ACS) combinations in BALB/c mice. Int J Nanomed, 11, 3265-76, 2016.
  6. Thakkar A, Chenreddy S, Wang J, and Prabhu S. Ferulic acid combined with aspirin demonstrates chemopreventive potential towards pancreatic cancer when delivered using chitosan-coated solid-lipid nanoparticles. Cell Biosci, 5, 46 (14 pages), 2015.
  7. Thakkar A, Chenreddy S, Wang J, Prabhu S. Evaluation of ibuprofen loaded solid lipid nanoparticles and its combination regimens for pancreatic cancer chemoprevention. Int J Oncol, 46, 1827-34, 2015.
  8. Wang J, Watanabe JH. Major ADC companies, current clinical trials, recent patents issued and patent applications, and cost analysis of drug therapy. In: Antibody-Drug Conjugates: The 21st Magic Bullets for Cancer. Wang J, Shen WC and Zaro J (Eds). AAPS Press/Springer, 2015, pp. 155-177.
  9. Zaro JL, Wang J, Shen WC. Summary and future directions. In: Antibody-Drug Conjugates: The 21st Magic Bullets for Cancer. Wang J, Shen WC and Zaro J (Eds). AAPS Press/Springer, 2015, pp. 237-252.